
Tuna recall at Walmart, Publix, Kroger, Costco, Trader Joe's. Botulism is possible
Problems with canned tuna cans can cause botulism and has caused a recall involving six of the nation's top seven grocery sellers, as well as independent grocers and two other well-known chains.
So heads up, Walmart, Kroger, Costco, Safeway, Publix, H-E-B, Harris Teeter and Trader Joe's tuna eaters.
Here's what's recalled from where and why the recall is happening:
What's the problem?
Tri-Union Seafood says a supplier said a problem with the pull tab can lid on some tuna products 'may compromise the integrity of the product seal (especially over time), causing it to leak, or worse, be contaminated with clostridium botulinum, a potentially fatal form of food poisoning.'
What you should do now
This might seem common sense, but don't eat recalled canned tuna if you have it, no matter how it looks or smells.
Return the tuna to the seller for a refund. Or throw it in the garbage. Tri-Union says you can reach out to it for a retrieval kit and coupon for a replacement.
For questions on this recall, contact Tri-Union at support@thaiunionhelp.zendesk.com or 833-374-0171, Monday through Friday, 9 a.m. to 5 p.m., Eastern time.
READ MORE: Salmonella causes a tahini recall in Florida, North Carolina, California, 19 total states
What canned tuna is recalled?
Listed by stores named in Tri-Union Seafood's recall notice, which is also where you'll find the exact lot codes.
Walmart: Van Camp's Solid Light Tuna in Oil, 5-ounce single cans and in four packs, best by Dec. 2, 2027; Genova Solid White Tuna in Olive Oil, 5-ounce cans, best by Dec. 12, 2027, or Jan. 24, 2028; Genova Yellowfin Tuna in Olive Oil, 5-ounce cans, best by Jan. 13, 2028 and Jan. 17, 2028, and four packs of 5-ounce cans, best by Dec. 13, 2027 and Jan. 21, 2008. Genova Yellowfin Tuna in Extra Virgin Olive Oil with Sea Salt, 5-ounce cans, best by Jan. 17, 2028. Walmart says this hit stores in Florida, North Carolina, South Carolina, California, Texas, Mississippi, Alabama, Arizona, Arkansas, Georgia, Louisiana, New Mexico, Nevada, Oklahoma, Oregon, Tennessee and Washington.
Costco: Genova Yellowfin Tuna in Olive Oil, six packs of 7-ounce cans, best by Jan. 21, Jan. 23 and Jan. 27, 2028, from stores in Florida and Georgia.
Publix: Genova Solid White Tuna in Olive Oil, 5-ounce cans, best by Dec. 12, 2027 or Jan. 24, 2028; Genova Yellowfin Tuna in Olive Oil, four packs of 5-ounce cans, best by Dec. 13, 2027 and Jan. 21, 2008.
Harris Teeter: Genova Solid White Tuna in Olive Oil, 5oz, best by Dec. 12, 2027 or Jan. 24, 2028.
Kroger, Fred Meyer and QFC stores: Genova Albacore Tuna Olive Oil, 5-ounce cans, best by Dec. 12, 2027 or Jan. 24, 2028. Tri-Union doesn't list, but Kroger does list, Chicken of the Sea Genova Tonno Tuna, four packs of 5-ounce cans, best by Dec. 13, 2027, and Jan. 23, 2028. Kroger says this affects stores in Lexington, Kentucky, the Louisville metropolitan area, Eastern Kentucky and Western Kentucky, North Carolina, South Carolina, Texas, Georgia, Nashville, Knoxville, Memphis metropolitan area, Southeastern Ohio, Eastern West Virginia, Virginia and Louisiana.
H-E-B: H-E-B Solid White Tuna in Water, four packs of 5-ounce cans, best by Dec. 12, 2027. The recall notice says H-E-B received recalled Genova tuna in 5-ounce cans also, but H-E-B's site lists only its store brand.
Safeway: Genova Solid White Tuna in Olive Oil, 5-ounce cans, best by Dec. 12, 2027 or Jan. 24, 2028; Genova Yellowfin Tuna in Olive Oil, 5-ounce cans, best by Jan. 13, 2028, and Jan. 17, 2028, and four packs of 5-ounce cans, best by Dec. 13, 2027, and Jan. 21, 2008. Genova Yellowfin Tuna in Extra Virgin Olive Oil with Sea Salt, 5-ounce cans, best by Jan. 17, 2028.
Trader Joe's: For the lot numbers to these products, all of which are store brands, check the Trader Joe's site.
Solid Light Yellowfin Tuna in Olive Oil, best by Jan. 10, 2028, stores in New Jersey and Pennsylvania.
Solid White Albacore Tuna No Salt Added, best by Jan. 8 or 9, 2028, stores in New York, New Jersey, Pennsylvania, Illinois, Indiana, Iowa, Kansas, Kentucky, Michigan, Minnesota, Missouri, Nebraska, Ohio and Wisconsin.
Solid White Albacore Tuna, Salt Added, best by Jan. 9, 2028, stores in New York, New Jersey, Pennsylvania, Illinois, Indiana, Iowa, Kansas, Kentucky, Michigan, Minnesota, Missouri, Nebraska, Ohio and Wisconsin.
Solid White Albacore Tuna, Low Sodium, best by Dec. 12, 2027, stores in New York, New Jersey, Pennsylvania, best by Dec. 13, 2027 for stores in Illinois, Indiana, Iowa, Kansas, Kentucky, Michigan, Minnesota, Missouri, Nebraska, Ohio and Wisconsin.
Solid White Albacore Tuna in Olive Oil, Salt Added, best by Jan. 13, 2028, for North Carolina, Pennsylvania, Delaware, Maryland, North Carolina, Ohio, Virginia, Illinois, Indiana, Iowa, Kansas, Kentucky, Michigan, Minnesota, Missouri, Nebraska, Ohio, Wisconsin and Washington, D.C.
Independent grocers in Florida, Pennsylvania and New Jersey: Van Camp's Solid Light Tuna in Oil, 5-ounce single cans and in four packs, best by Dec. 2, 2027.
Independent grocers in Florida, North Carolina, California, Texas, Alabama, Arkansas, Arizona, Georgia, New Jersey and Tennessee: Genova Solid White Tuna in Olive Oil, 5-ounce cans, best by Dec. 12, 2027 or Jan. 24, 2028; Genova Yellowfin Tuna in Olive Oil, 5-ounce cans, best by Jan. 13, 2028, and Jan. 17, 2028, and four packs of 5-ounce cans, best by Dec. 13, 2027, and Jan. 21, 2008. Genova Yellowfin Tuna in Extra Virgin Olive Oil with Sea Salt, 5-ounce cans, best by Jan. 17, 2028.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
an hour ago
- Business Wire
Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Tuesday, June 17, 2025, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 ended March 31, 2025, and provide a corporate update. The conference call is being webcast live, and a link can be found under 'Events' in the Investors section of the Company's website. Participants may register to join the live call by following the link here to receive the dial-in numbers and unique PIN to access the call. Those who plan on participating are advised to join 15 minutes prior to the start time. A webcast replay of the call will be available on Vistagen's website about 24 hours after the end of the live conference call and will be accessible for at least 30 days. About Vistagen Headquartered in South San Francisco, CA, Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a broad and diverse pipeline of clinical-stage product candidates from a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists to peripheral receptors on human nasal chemosensory neurons and are designed to rapidly activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. They are designed to achieve therapeutic benefits without requiring absorption into the blood or uptake into the brain, giving them the potential to be a safer alternative to other pharmacological options if successfully developed and approved. Vistagen's neuroscience pipeline also includes an oral prodrug with potential to treat certain neurological conditions involving the NMDA receptor. Vistagen is passionate about developing transformative treatment options to improve the lives of individuals underserved by the current standard of care for multiple highly prevalent indications, including social anxiety disorder, major depressive disorder, and multiple women's health conditions, including vasomotor symptoms (hot flashes) associated with menopause. Connect at
Yahoo
2 hours ago
- Yahoo
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics, Inc. to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
WILMINGTON, Del., June 12, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx" or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE," or the "Company"), a multi-site clinical care delivery organization and wholly-owned subsidiary of NRx, today announced participation in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference, scheduled for June 16–17, 2025. Dr. Jonathan Javitt, Founder, Chairman and Chief Executive Officer of NRx Pharmaceuticals and Co-CEO of HOPE, will deliver a corporate presentation highlighting the company's latest advances. The presentation will be available on demand to registered attendees beginning at 7:00 a.m. Eastern Time on Monday, June 16, 2025. In addition, the company will be participating in one-on-one meetings with investors throughout the conference. Please request 1:1 meetings on the HCW conference website listed below. Event Details: Date: Presentation available on-demand Monday, June 16, beginning at 7:00 a.m. ET for registered conference attendees Registration: H.C. Wainwright 6th Annual Neuro Perspectives Registration NRx Website: NRx Events About NRx Pharmaceuticals, Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy, for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential as a treatment for complicated UTI. NRx recently filed an Abbreviated New Drug Application (ANDA) for NRX-100 (preservative free IV ketamine) for use in ketamine's currently approved indications. Additionally, the Company has initiated a New Drug Application filing for NRX-100 for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality and has filed a patent for this novel formulation with the US Patent and Trademark Office. About HOPE Therapeutics, Therapeutics, Inc. ( a subsidiary of NRx Pharmaceuticals, is a Healthcare delivery company that is building a best-in-class network of interventional psychiatry clinics to offer ketamine, transcranial magnetics stimulation (TMS), and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy. Notice Regarding Forward-Looking StatementsThe information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the satisfaction of closing conditions necessary to consummate the acquisition of Kadima, Neurospa and Dura, and obtaining financing necessary to consummate the acquisitions. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, liquidity, whether the USPTO approves the Company's patent, and whether the FDA will approve the Company's NDA. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise. For further information:Matthew Duffy Brian Korb Co-CEO, Hope Therapeutics, Inc. Managing Partner, astr partners Chief Business Officer, NRx Pharmaceuticals, Inc. (917) 653-5122 mduffy@ View original content to download multimedia: SOURCE NRx Pharmaceuticals, Inc.
Yahoo
16 hours ago
- Yahoo
8 ice cream flavors recalled in Ohio
WAUSEON, Ohio — An Ohio-based creamery has announced a voluntary recall due to undeclared allergens in eight of their ice cream flavors. According to the Ohio Department of Agriculture, Turkeyfoot Creek Creamery of Wauseon, Ohio, is recalling the following flavors of ice cream; Avalanche, Chocolate Peanut Butter, Chocolate Strawberry, Chocolate Brownie Bites, Cookies and Cream, Cookie Dough, Cacao and Mocha. Massive egg recall hits Ohio Walmart stores The affected products are all packaged in pint containers and were distributed to six stores, located in Canton, Cleveland, West Unity, and Arlington, Ohio. As well, as two stores located out of state, with one in Fort Wayne, Indiana, and the other in Hudson, Michigan, read a press release from the Ohio Department of Agriculture. Young mother killed in shooting at Cleveland Metroparks Mill Creek Falls 'There have been no reports of illness involving products addressed in this recall, however, individuals exhibiting signs or symptoms of an allergic reaction after consuming Turkeyfoot Creek Creamery Ice Cream involved in this recall should contact a physician immediately,' stated the release. All affected products have been removed from store shelves. Consumers can return recalled products to the place of purchase for a refund. Consumers with questions can call 419-583-7124. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.